Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Johnson & Johnson (NY:JNJ)

244.27 +0.94 (+0.39%)
Streaming Delayed Price Updated: 3:11 PM EST, Feb 18, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Johnson & Johnson

< Previous 1 2 3 4 5 6 7 8 9
...
99 100 Next >
News headline image
Health Care Sector (XLV) Shows Resilience Amid Tech Volatility and Strong Jobs Data
As the broader market grappled with a violent valuation reset in the technology sector, the health care industry emerged as a critical anchor for investors in early 2026. The Health Care Select Sector... 
Via MarketMinute
Topics Artificial Intelligence ETFs Earnings
News headline image
FDA Grants Breakthrough Status To Johnson & Johnson's Cancer Drug For Advanced Head and Neck Cancer ↗
FDA grants Breakthrough Therapy status to Rybrevant for advanced cancer while Trellus Health extends IBD support contract. 
Via Benzinga
News headline image
Behind the Scenes of Johnson & Johnson's Latest Options Trends ↗
 
Via Benzinga
News headline image
Johnson & Johnson's New FDA Approval Lets Lung Cancer Patients Switch To Monthly Dosing Sooner ↗
FDA approves monthly dosing for J&J's Rybrevant Faspro with Lazcluze, offering faster, easier treatment for EGFR lung cancer. 
Via Benzinga
Johnson & Johnson (NYSE:JNJ) Stands Out as a High-Quality Dividend Aristocrat for Income Investors ↗
Via Chartmill
Johnson & Johnson's Getting Back to Double-Digit Growth. Has the Stock Become a Bargain Buy? ↗
Via The Motley Fool
News headline image
The Seven-Thousand Siege: S&P 500’s Historic Breach and the Great Tech Pivot of 2026
In a watershed moment for global equity markets, the S&P 500 (INDEXSP:.INX) briefly conquered the psychological 7,000-point milestone in late January 2026, marking the fastest 1,000-point ascent in the... 
Via MarketMinute
Topics Artificial Intelligence ETFs Earnings
News headline image
ASCO GU 2026: Merck and Protara Poised to Disrupt Bladder and Kidney Cancer Standards
As the oncology community prepares to descend upon San Francisco for the 2026 ASCO Genitourinary (GU) Cancers Symposium from February 26–28, investors and clinicians alike are bracing for data that... 
Via MarketMinute
Topics Intellectual Property
News headline image
Jury: Johnson & Johnson Liabile in Case Linking Baby Powder to Cancer ↗
On Friday, a Pennsylvania state-court jury in Philadelphia ordered Johnson & Johnson (NYSE: JNJ) to pay $250,000 to the family of Gayle Emerson, finding the company liable in a case blaming its talc... 
Via Benzinga
News headline image
Volatility Returns to Wall Street: VIX Surges 18% as AI Fatigue Triggers Massive Three-Day Sector Rotation
The U.S. equity markets faced a grueling three-session losing streak ending Friday, February 13, 2026, as a wave of "AI capex fatigue" and disappointing corporate guidance sent investors scurrying for... 
Via MarketMinute
Topics Artificial Intelligence Bonds Economy
News headline image
"Blowout" Jobs Report Ignites 2026 Growth Hopes as Unemployment Hits 4.3% Floor
The U.S. labor market kicked off 2026 with an unexpected surge, as the January nonfarm payrolls report shattered analyst expectations and provided a much-needed jolt to the economic outlook. Adding... 
Via MarketMinute
Topics Artificial Intelligence Economy Workforce
News headline image
The Great Rebound: US M&A Market Ignites as Megadeals Surge 111% in AI-Driven Supercycle
The United States merger and acquisition (M&A) landscape has entered a transformative era in early 2026, marking a definitive end to the deal-making drought that plagued the previous two years. Driven... 
Via MarketMinute
Topics Artificial Intelligence Economy Energy
News headline image
Is Johnson & Johnson a Buy, Sell, or Hold in 2026? ↗
This reliable dividend payer may be just what the doctor ordered. 
Via The Motley Fool
Topics Artificial Intelligence Intellectual Property Lawsuit
News headline image
5 Stocks and ETFs to Help Shield Your Portfolio During Volatility ↗
Via MarketBeat
Topics ETFs
News headline image
Johnson &amp; Johnson Reports 90% AFib Freedom In Early Heart Device Study ↗
Johnson & Johnson shared early AFib study results showing 90% success and no safety issues, but the stock lagged as healthcare stocks outperformed broader markets. 
Via Benzinga
News headline image
What is Considered a Good Stock Dividend? 2 Healthcare Stocks That Fit the Bill. ↗
These companies pay very healthy dividends. 
Via The Motley Fool
Topics Bonds
News headline image
Eli Lilly Booms, Then Busts: Stellar Guidance vs Hims Undercut ↗
Via MarketBeat
News headline image
Johnson & Johnson Is A Resilient Blue-Chip Stock And It Just Hit New All-Time Highs ↗
Johnson & Johnson (JNJ) has a diversified business model that makes it resilient through economic cycles. JNJ is trading at new all-time highs. 
Via Talk Markets
News headline image
Johnson & Johnson Is a Resilient Blue-Chip Stock and It Just Hit New All-Time Highs
Johnson & Johnson (JNJ) has a diversified business model that makes it resilient through economic cycles. JNJ is trading at new all-time highs. The stock maintains a 100% “Buy” technical opinion from... 
Via Barchart.com
News headline image
The Great Pipeline Grab: Life Sciences Deal Volume Skyrockets 82% as Big Pharma Battles the Patent Cliff
The life sciences sector has entered 2026 in the midst of a historic transformation, as deal volume and value surged by a staggering 82% over the past year. This "Great Rebound," fueled by a... 
Via MarketMinute
Topics Artificial Intelligence Economy Intellectual Property
News headline image
Roivant Sciences (ROIV): Anatomy of a 15% Surge and the Future of the ‘Vant’ Model
As of February 6, 2026, Roivant Sciences (Nasdaq: ROIV) has firmly established itself as the preeminent "capital allocator" of the biotechnology sector. The company made headlines today with a... 
Via Finterra
Topics ETFs Economy Initial Public Offering
News headline image
The $14.5 Billion Homecoming: Boston Scientific Reclaims the Neurovascular Throne with Penumbra Acquisition
In a move that has sent shockwaves through the medical technology sector, Boston Scientific (NYSE:BSX) announced on January 15, 2026, a definitive agreement to acquire Penumbra (NYSE:PEN) for... 
Via MarketMinute
Topics Supply Chain
News headline image
Navigating the MedTech Correction: A Deep-Dive into Boston Scientific (NYSE: BSX)
February 5, 2026 The medical technology landscape experienced a seismic shift this week as one of its long-standing titans, Boston Scientific (NYSE: BSX), faced a "valuation reset" that has left... 
Via Finterra
Topics Product Recall World Trade
News headline image
The Pharma Reckoning: 2026 Earnings Unveil a New Era of 'TrumpRx' Deals and Looming Patent Cliffs
As the pharmaceutical industry enters the heart of its Q4 2025 earnings season this February 2, 2026, a clear divide has emerged between the high-flying giants of the metabolic gold rush and those... 
Via MarketMinute
Topics Economy Government Intellectual Property
News headline image
The Biological Singularity: How AlphaFold 3 Is Rewriting the Blueprint of Drug Discovery
As of early 2026, the promise of “digital-first” drug discovery has shifted from a speculative horizon to a tangible industrial reality. Since its groundbreaking release in May 2024, AlphaFold 3... 
Via TokenRing AI
Topics Artificial Intelligence
News headline image
Where Will AbbVie Be in 5 Years? ↗
A prediction for AbbVie in 2031: The drugmaker will be bigger and kinglier. 
Via The Motley Fool
Topics Intellectual Property
News headline image
All It Takes Is $13,000 Invested in Each of These 2 Dividend Kings to Help Generate $1,000 in Passive Income in 2026 ↗
Consumer staples stocks being out of favor is an impeccable buying opportunity for value investors. 
Via The Motley Fool
Topics Earnings
News headline image
3 Vanguard ETFs to Buy to Protect Your Portfolio from a Potential Stock Market Crash ↗
These Vanguard funds won't necessarily keep you from losing money if the market crashes. But they can help cushion the blow. 
Via The Motley Fool
Topics Bonds ETFs Regulatory Compliance
News headline image
Looking for Passive Income in 2026? 3 Dividend Kings to Buy Hand Over Fist ↗
These market giants make great long-term investments. 
Via The Motley Fool
News headline image
1 Super-Safe High-Yield Dividend King Stock to Buy Even if There's a Stock Market Sell-Off in 2026 ↗
Near a 12-year low, Kimberly-Clark may be one of the best deep value stocks for income investors to buy in 2026. 
Via The Motley Fool
Topics Artificial Intelligence Economy World Trade
< Previous 1 2 3 4 5 6 7 8 9
...
99 100 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.